加拿大临床实践指南：基于植物的大麻和大麻素类产品在慢性非癌症疼痛及合并症管理中的应用：系统文献综述方案。
Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review.
机构信息
Canadian AIDS Society, Ottawa, Ontario, Canada.
Department of Psychology, University of British Columbia, Kelowna, British Columbia, Canada.
出版信息
BMJ Open. 2020 May 24;10(5):e036114. doi: 10.1136/bmjopen-2019-036114.
INTRODUCTION
Chronic pain and co-occurring disorders, such as sleep disorders, anxiety, depression, post-traumatic stress disorder and substance use disorders, are among the most common conditions for which cannabis and cannabinoid-based products derived from the cannabis plant (CBP) are used for therapeutic purposes. However, healthcare providers report that they lack sufficient information on the risks, benefits and appropriate use of cannabis and CBP derived from the cannabis plant for therapeutic purposes.
METHODS AND ANALYSIS
We will conduct a systematic review of studies investigating the use of cannabis and CBP derived from the cannabis plant for the treatment of chronic pain and co-occurring conditions. Randomised controlled trials, meta-analyses and observational studies will be prioritised. We will exclude reviews of cannabinoid mechanisms of actions, commentary articles and narrative reviews. The primary outcome of interest will be efficacy in relieving chronic pain. Secondary outcomes will be efficacy in ameliorating conditions such as sleep disorders, anxiety, depression, post-traumatic stress disorder and substance use disorders. We will search electronic bibliographic databases including Academic Search Complete, Cochrane Database of Systematic Reviews, Evidence based Medicine Reviewes, OVID Medline, PsychINFO, PubMed, CINAHL and Web of Science. Two reviewers will conduct screening and data collection independently. Study level of bias will be assessed using the Cochrane Risk of Bias Assessment Tool for randomised controlled trials and non-randomised studies. Narrative analysis will be utilised to interpret the data.
ETHICS AND DISSEMINATION
The results of this systematic review will inform guideline development for the use of cannabis and CBP derived from the cannabis plant in the management of chronic pain and co-occurring conditions. Areas requiring further study will also be highlighted.
PROSPERO REGISTRATION NUMBER
CRD42020135886.
简介
慢性疼痛和共病，如睡眠障碍、焦虑、抑郁、创伤后应激障碍和物质使用障碍，是最常见的疾病之一，大麻和大麻植物衍生的大麻素类产品（CBP）被用于治疗这些疾病。然而，医疗保健提供者报告说，他们缺乏关于大麻和 CBP 用于治疗目的的风险、益处和适当使用的足够信息。
方法和分析
我们将对研究大麻和大麻植物衍生的 CBP 用于治疗慢性疼痛和共病的使用情况进行系统评价。将优先考虑随机对照试验、荟萃分析和观察性研究。我们将排除关于大麻素作用机制的综述、评论文章和叙述性综述。主要观察结果将是缓解慢性疼痛的疗效。次要结果将是改善睡眠障碍、焦虑、抑郁、创伤后应激障碍和物质使用障碍等疾病的疗效。我们将搜索电子书目数据库，包括 Academic Search Complete、Cochrane 系统评价数据库、循证医学评论、OVID Medline、PsychINFO、PubMed、CINAHL 和 Web of Science。两名评审员将独立进行筛选和数据收集。使用 Cochrane 随机对照试验和非随机研究偏倚风险评估工具评估研究水平的偏倚。将利用叙述性分析来解释数据。
伦理和传播
这项系统评价的结果将为大麻和大麻植物衍生的 CBP 在慢性疼痛和共病管理中的使用指南的制定提供信息。还将强调需要进一步研究的领域。
PROSPERO 注册号：CRD42020135886。
Zotero 插件